Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells

Human Gene Therapy

Volumn 22, Issue 1, 2011, Pages 107-115

  Feldman, Steven A ^a   Goff, Stephanie L ^b   Xu, Hui ^a   Black, Mary A ^a   Kochenderfer, James N ^a   Johnson, Laura A ^c   Yang, James C ^a   Wang, Qiong ^a   Parkhurst, Maria R ^a   Cross, Scott ^d   Morgan, Richard A ^a   Cornetta, Kenneth ^d   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Columbia University ^*  (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMARETROVIRAL VECTOR; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ARTICLE; CLEARANCE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); EX VIVO STUDY; FILTRATION; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; LARGE SCALE PRODUCTION; LEUKOCYTE; NONHUMAN; SOLID TUMOR; SUPERNATANT; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; FILTRATION; GAMMARETROVIRUS; GENE THERAPY; GENETIC VECTORS; MICE; VIRUS CULTIVATION;

EID: 79951863196     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.064     Document Type: Article

References (24)

1. Center for Biologics Evaluation and Research. (1998). Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (Rockville, MD).
2. Center for Biologics Evaluation and Research. (2006). Guidance for Industry: INDs-Approaches to Complying with CGMP During Phase 1: Draft Guidance. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (Rockville, MD).
3. Cohen, C.J., Zhao, Y., Zheng, Z., Rosenberg, S.A., and Morgan, R.A. (2006). Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66, 8878-8886. (Pubitemid 44449206)
4. Cornetta, K., Matheson, L., and Ballas, C. (2005). Retroviral vector production in the National Gene Vector Laboratory at Indiana University. Gene Ther. 12(Suppl. 1), S28-S35. (Pubitemid 41541751)
5. Ghani, K., Cottin, S., Kamen, A., and Caruso, M. (2007). Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media. Gene Ther. 14, 1705-1711. (Pubitemid 350238447)
6. Ghani, K., Wang, X., de Campos-Lima, P.O., Olszewska, M., Kamen, A., Rivière, I., and Caruso, M. (2009). Efficient human hematopoietic cell transduction using RD114- and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media. Hum. Gene Ther. 20, 966-974.
7. Hughes, M.S., Yu, Y.Y.L., Dudley, M.E., Zheng, Z., Robbins, P.F., Li, Y., Wunderlich, J., Hawley, R.G., Moayeri, M., Rosenberg, S.A., and Morgan, R.A. (2005). Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 16, 457-472. (Pubitemid 40647143)
8. Johnson, L.A., Heemskerk, B., Powell, D.J., Jr., Cohen, C.J., Morgan, R.A., Dudley, M.E., Robbins, P.F., and Rosenberg, S.A. (2006). Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 177, 6548-6559. (Pubitemid 44628874)
9. Johnson, L.A., Morgan, R.A., Dudley, M.E., Cassard, L., Yang, J.C., Hughes, M.S., Kammula, U.S., Royal, R.E., Sherry, R.M., Wunderlich, J.R., Lee, C.C., Restifo, N.P., Schwarz, S.L., Cog-dill, A.P., Bishop, R.J., Kim, H., Brewer, C.C., Rudy, S.F., VanWaes, C., Davis, J.L., Mathur, A., Ripley, R.T., Nathan, D.A., Laurencot, C.M., and Rosenberg, S.A. (2009). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546.
10. Kochenderfer, J.N., Feldman, S.A., Zhao, Y., Xu, H., Black, M.A., Morgan, R.A., Wilson, W.H., and Rosenberg, S.A. (2009). Construction and preclinical evaluation of an anticD19 chi-meric antigen receptor. J. Immunother. 32, 689-702.
11. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., Zheng, Z., Nahvi, A., de Vries, C.R., Rogers-Freezer, L.J., Mavroukakis, S.A., and Rosenberg, S.A. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129. (Pubitemid 44547756)
12. Office of Biologics Research and Review, Center for Biologics Evaluation and Research. (1985). Points to Consider in the Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology. U.S. Department of Health and Human Services, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (Rock-ville, MD).
13. Office of Biologics Research and Review, Center for Biologics Evaluation and Research. (1993). Points to Consider in the Use of Cell Lines to Produce Biologicals. U.S. Department of Health and Human Services, Food and Drug Admininstration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (Rockville, MD).
14. Onodera, M., Yachie, A., Nelson, D.M., Welchlin, H., Morgan, R.A., and Blaese, R.M. (1997). A simple and reliable method for screening retroviral producer clones without selectable markers. Hum. Gene Ther. 8, 1189-1194. (Pubitemid 27394127)
15. Parkhurst, M.R., Joo, J., Riley, J.P., Yu, Z., Li, Y., Robbins, P.F., and Rosenberg, S.A. (2009). Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin. Cancer Res. 15, 169-180.
16. Pizzato, M., Merten, O.W., Blair, E.D., and Takeuchi, Y. (2001). Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors. Gene Ther. 8, 737-745. (Pubitemid 32509787)
17. Przybylowski, M., Hakakha, A., Stefanski, J., Hodges, J., Sadelain, M., and Riviere, I. (2006). Production scale-up and validation of packaging cell clearance of clinical-grade ret-roviral vector stocks produced in cell factories. Gene Ther. 13, 95-100. (Pubitemid 41823856)
18. Reeves, L., and Cornetta, K. (2000). Clinical retroviral vector production: Step filtration using clinically approved filters improves titers. Gene Ther. 7, 1993-1998. (Pubitemid 32036764)
19. Reeves, L., Smucker, P., and Cornetta, K. (2000). Packaging cell line characteristics and optimizing retroviral vector titer: The National Gene Vector Laboratory experience. Hum. Gene Ther. 11, 2093-2103.
20. Rosenberg, S.A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R.A., Moen, R., Karson, E.M., Lotze, M.T., Yang, J.C., Topa-lian, S.L., Merino, M.J., Culver, K., Miller, A.D., Blaese, R.M., and Anderson, W.F. (1990). Gene transfer into humans- immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570-578. (Pubitemid 20260084)
21. Rosenberg, S.A., and Dudley, M.E. (2009). Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21, 233-240.
22. Topalian, S., Solomon, D., and Rosenberg, S. (1989). Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142, 3714-3725. (Pubitemid 19137511)
23. Wang, Q.J., Hanada, K.-I., and Yang, J.C. (2008). Characterization of a novel nonclassical T cell clone with broad reactivity against human renal cell carcinomas. J. Immunol. 181, 3769-3776.
24. Wu, S.C., Huang, G.Y., and Liu, J.H. (2002). Production of ret-rovirus and adenovirus vectors for gene therapy: A comparative study using microcarrier and stationary cell culture. Biotechnol. Prog. 18, 617-622. (Pubitemid 34623237)